Lupin Limited has signed a licence and supply agreement with Spektus Pharma to commercialise DeslaFlex™ in Canada, strengthening its central nervous system (CNS) portfolio in the region.
DeslaFlex™ is a novel antidepressant developed using Spektus Pharma’s proprietary Flexitab™ oral drug-delivery platform. The innovative formulation is designed to provide greater dosing flexibility, offering a differentiated treatment option for patients diagnosed with Major Depressive Disorder (MDD).
Under the agreement, Lupin will leverage its established commercial presence and distribution network in Canada to introduce DeslaFlex™ to the market. The collaboration combines Lupin’s strong specialty pharmaceutical capabilities with Spektus Pharma’s expertise in developing advanced, value-added formulations.
The partnership marks a strategic step in expanding Lupin’s CNS footprint in Canada. By adding DeslaFlex™ to its portfolio, the company aims to provide physicians and patients with enhanced therapeutic flexibility in managing depression, a condition that continues to impact millions globally.
Claus Jepsen, President – Global Specialty at Lupin, stated that the agreement reinforces the company’s long-term commitment to Canadian healthcare. He highlighted that the introduction of DeslaFlex™ will enable clinicians to deliver more personalised, patient-focused treatment approaches in the management of Major Depressive Disorder.